ID   HAK-3
AC   CVCL_E419
DR   Wikidata; Q54872382
RX   PubMed=10347112;
RX   PubMed=10493947;
CC   Population: Japanese.
CC   Doubling time: ~26 hours (Note=At 52th passage) (PubMed=10493947).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3098; Hepatitis C infection
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 29-06-23; Version: 10
//
RX   PubMed=10347112; DOI=10.1002/hep.510290624;
RA   Yano H., Iemura A., Haramaki M., Ogasawara S., Takayama A., Akiba J.,
RA   Kojiro M.;
RT   "Interferon alfa receptor expression and growth inhibition by
RT   interferon alfa in human liver cancer cell lines.";
RL   Hepatology 29:1708-1717(1999).
//
RX   PubMed=10493947; DOI=10.3892/ijo.15.4.669;
RA   Utsunomiya I., Iemura A., Yano H., Akiba J., Kojiro M.;
RT   "Establishment and characterization of a new human hepatocellular
RT   carcinoma cell line, HAK-3, and its response to growth factors.";
RL   Int. J. Oncol. 15:669-675(1999).
//